- Home
- LILAK vs NVCR Comparison
LILAK vs NVCR Comparison
Compare LILAK & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- NVCR
- Stock Information
- Founded
- LILAK 2017
- NVCR 2000
- Country
- LILAK Bermuda
- NVCR Switzerland
- Employees
- LILAK N/A
- NVCR N/A
- Industry
- LILAK Cable & Other Pay Television Services
- NVCR Medical/Dental Instruments
- Sector
- LILAK Telecommunications
- NVCR Health Care
- Exchange
- LILAK Nasdaq
- NVCR Nasdaq
- Market Cap
- LILAK 1.1B
- NVCR 1.9B
- IPO Year
- LILAK N/A
- NVCR 2015
- Fundamental
- Price
- LILAK $6.60
- NVCR $17.71
- Analyst Decision
- LILAK Buy
- NVCR Buy
- Analyst Count
- LILAK 3
- NVCR 6
- Target Price
- LILAK $10.27
- NVCR $32.83
- AVG Volume (30 Days)
- LILAK 1.1M
- NVCR 1.6M
- Earning Date
- LILAK 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- LILAK N/A
- NVCR N/A
- EPS Growth
- LILAK N/A
- NVCR N/A
- EPS
- LILAK N/A
- NVCR N/A
- Revenue
- LILAK $4,441,000,000.00
- NVCR $621,711,000.00
- Revenue This Year
- LILAK $2.45
- NVCR $5.56
- Revenue Next Year
- LILAK $3.11
- NVCR $9.19
- P/E Ratio
- LILAK N/A
- NVCR N/A
- Revenue Growth
- LILAK N/A
- NVCR 18.27
- 52 Week Low
- LILAK $4.23
- NVCR $14.17
- 52 Week High
- LILAK $10.93
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- LILAK 74.11
- NVCR 51.32
- Support Level
- LILAK $5.78
- NVCR $17.53
- Resistance Level
- LILAK $6.53
- NVCR $18.70
- Average True Range (ATR)
- LILAK 0.24
- NVCR 0.72
- MACD
- LILAK 0.09
- NVCR 0.09
- Stochastic Oscillator
- LILAK 96.21
- NVCR 60.56
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.